Search Results
Jun 19, 2025, 17:46 ET HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight
DF1001. Dato-DXd is an experimental TROP2-targeted ADC, developed using Daiichi Sankyo's proprietary DXd ADC Technology. It is one of six DXd ADCs in their oncology pipeline and a key program in AstraZeneca's ADC scientific platform. In collaboration with Sapporo Medical University,
More news about: DelveInsight Business Research, LLP
Jun 19, 2025, 17:31 ET Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline | DelveInsight
significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine tumors. Advancements in antibody-drug conjugate (ADC) technology and increasing clinical trial activity are propelling the development of DLL3-targeted candidates. Growing interest from biopharma companies
More news about: DelveInsight Business Research, LLP
Jun 19, 2025, 08:00 ET Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that Dave Lennon, PhD, President and CEO, and David Dornan,
More news about: Whitehawk Therapeutics, Inc.
Jun 18, 2025, 19:08 ET LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma
and Asia, the company is solidifying its position in the CDMO market not only for antibody therapeutics but also for ADC modalities. LOTTE BIOLOGICS aims to secure clients by providing an integrated service through collaboration, delivering superior and trustworthy solutions.
More news about: LOTTE BIOLOGICS
Jun 18, 2025, 19:00 ET LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma
and Asia, the company is solidifying its position in the CDMO market not only for antibody therapeutics but also for ADC modalities. LOTTE BIOLOGICS aims to secure clients by providing an integrated service through collaboration, delivering superior and trustworthy solutions.
More news about: LOTTE BIOLOGICS
Jun 16, 2025, 09:03 ET Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals,
More news about: Fosun Pharma
Jun 16, 2025, 08:30 ET BioDlink's Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion
Indonesia, and Argentina and also passed antibody drug and ADC EU QP inspection 4 times in past two years. BioDlink's global-quality system ensures robust commercial supply, delivering more than 100 clinical
More news about: BioDlink Biopharm Co., Ltd.
Jun 16, 2025, 07:15 ET ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform
More news about: ADC Therapeutics SA
Jun 12, 2025, 08:33 ET GlycoNex Announces Publication of Preclinical Study on GNX1021, a Novel Glycan-Targeted ADC for Gastric Cancer
help accelerate our path to the clinic." Recent landmark deals in the ADC field highlight the strong licensing potential of early-stage assets, with total deal sizes reaching several billion dollars. As the global ADC market exceeded USD 160 billion in 2023, GlycoNex
More news about: GlycoNex, Inc.
Jun 12, 2025, 06:45 ET ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
malignancies and earlier lines of therapy. About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for
More news about: ADC Therapeutics SA
Jun 12, 2025, 06:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform
More news about: ADC Therapeutics SA
Jun 12, 2025, 05:17 ET Sobi share new clinical data across multiple hematologic diseases at EHA 2025
procedure. About Zynlonta® (loncastuximab tesirine) Zynlonta® (loncastuximab tesirine) is a CD19-directed antibody drug conjugate (ADC). Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade
More news about: Swedish Orphan Biovitrum AB
Jun 11, 2025, 07:00 ET Simtra BioPharma Solutions and MilliporeSigma Announce Strategic Alliance for Antibody Drug Conjugates Drug Substance and Drug Product Manufacturing Services
expedite timelines. The ADC pipeline is experiencing strong growth with an increasing number of biopharma companies developing assets in this space, and currently more than 70% of these drugs are manufactured by CDMOs. A Roots Analysis study showed the market for ADC manufacturing is $1.79
More news about: Simtra BioPharma Solutions
Jun 10, 2025, 23:17 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Jun 10, 2025, 16:05 ET Agree Realty Declares Monthly Common and Preferred Dividends
Mich., June 10, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256
More news about: Agree Realty Corporation
Jun 10, 2025, 11:48 ET Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel DC aseets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Jun 10, 2025, 10:05 ET O Reino Hachemita, da Jordânia, anuncia novo centro de inovação oceânica em parceria com a inovadora empresa de tecnologia azul Voyacy Regen
Development CorporationA Aqaba Development Corporation (ADC) é o braço de investimento do governo para a Zona Econômica Especial de Aqaba (ASEZ), possuindo e gerenciando ativos-chave, incluindo portos, aeroportos e terras. A ADC impulsiona o crescimento sustentável ao possibilitar investimentos
More news about: Voyacy Regen
Jun 10, 2025, 10:01 ET El Reino Hachemita de Jordania anuncia un nuevo centro de innovación oceánica en asociación con la innovadora empresa de tecnología azul Voyacy Regen
CorporationAqaba Development Corporation (ADC) es el brazo de inversión del gobierno para la Zona Económica Especial de Aqaba (ASEZ, por sus siglas en inglés), que posee y administra activos clave, como puertos, aeropuertos y terrenos. ADC impulsa el crecimiento sostenible al permitir la inversión
More news about: Voyacy Regen
Jun 10, 2025, 09:56 ET Le Royaume hachémite de Jordanie annonce la création d'un nouveau centre d'innovation océanique en partenariat avec Voyacy Regen, une entreprise de technologie bleue innovante
Development CorporationAqaba Development Corporation (ADC) est le bras financier du gouvernement pour la zone économique spéciale d'Aqaba (ASEZ), possédant et gérant des actifs essentiels, notamment des ports, un aéroport et des terres. ADC stimule la croissance durable en favorisant les investissements
More news about: Voyacy Regen
Jun 10, 2025, 09:53 ET 요르단 하심 왕국, 혁신적인 블루 테크 기업 보야시 리젠과 협력해 새로운 해양 혁신 허브 구축 계획
바다가 함께 번영할 수 있는 기후 회복력이 강한 세상을 창조하는 것을 목표로 한다. 후세인 알-사파디(Hussein Al-Safadi) 아카바 개발 공사(Aqaba Development Corporation•ADC) CEO는 "오늘 발표는 지속 가능한 관행과 기후 행동을 요르단 경제 성장의 핵심적 요소로 만들면서 미래 세대를 위해 왕국의 환경과 자연 자원을 보호하는 안전장치를 마련하려는 우리 노력에서 중요한 단계"라고 말했다. 그는 이어 "아카바 해양 공원은 아카바에 대한 압둘라 2세 국왕의 비전에
More news about: Voyacy Regen
Jun 10, 2025, 07:40 ET OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary
More news about: EVERSANA
Jun 10, 2025, 07:14 ET Nuevo centro de innovación oceánica en asociación con la innovadora empresa de tecnología azul Voyacy Regen
Development CorporationLa Aqaba Development Corporation (ADC) es el brazo inversor del gobierno para la Zona Económica Especial de Aqaba (ASEZ), que posee y gestiona activos clave como puertos, aeropuerto y terrenos. La ADC impulsa el crecimiento sostenible facilitando la inversión y las infraestructuras
More news about: Voyacy Regen
Jun 10, 2025, 07:00 ET Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypesThe ADCElerate1 trial will enroll patients in the US
More news about: Adcendo
Jun 10, 2025, 07:00 ET Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypesThe ADCElerate1 trial will enroll patients in the US
More news about: Adcendo
Jun 10, 2025, 06:00 ET Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
). The agreement, officially signed on June 6, brings together Medicovestor's proprietary ADC platforms—ADoBind, a novel dimeric antibody architecture, and ADoTope, a bi-epitope targeting system—with Sanyou's globally leading AI-STAL (Artificial
More news about: Sanyou Bio